NCT02236013View on ClinicalTrials.gov

A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 7, 2015

Primary Completion Date

July 26, 2021

Study Completion Date

July 26, 2021

Conditions

Acute Myeloid Leukemia

Interventions

DRUG

Gilteritinib

Oral

DRUG

Idarubicin

lyophilized powder administered intravenously

DRUG

Cytarabine

solution administered intravenously

DRUG

Daunorubicin

solution administered intravenously

Trial Locations (10)

10032

Site US10002, New York

19104

Site US10006, Philadelphia

21231

Site US10001, Baltimore

44106

Site US10014, Cleveland

60611

Site US10004, Chicago

66205

Site US10009, Westwood

73104

Site US10019, Oklahoma City

78229

Site US10010, San Antonio

90095

Site US10003, Los Angeles

06520

Site US10013, New Haven

All Listed Sponsors

lead

Astellas Pharma Global Development, Inc.

INDUSTRY

NCT02236013 - A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia | Biotech Hunter | Biotech Hunter